Trial
NCT00664573
104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
Baminercept alfa (BG9924)
Why stopped
Analysis of data from 104RA202 failed to meet primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-21